Perlegen Sciences
Perlegen Sciences is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Perlegen Sciences.
Perlegen Sciences is a company.
Key people at Perlegen Sciences.
Key people at Perlegen Sciences.
Perlegen Sciences was a biotechnology company founded in 2000 focused on identifying patterns of genetic variation between individuals to improve patient care and uncover genetic foundations of diseases.[1][4][5] It specialized in human genomics research, participating in projects like the International HapMap Project, and developed genotyping protocols using Affymetrix oligonucleotide arrays for high-throughput analysis.[1] The company served pharmaceutical and research sectors by advancing pharmacogenomics and disease genetics but ceased operations on October 30, 2009, with no evident growth momentum post-closure.[1][2]
Perlegen Sciences was founded in late 2000 by David R. Cox, a key figure in genomics, with the initial mission to map genetic variations for medical applications.[1][4][5] The idea emerged amid the post-Human Genome Project era, emphasizing high-resolution genotyping to study individual differences.[1][3] Early traction included active involvement in the International HapMap Project, developing protocols for multiplexing PCR-amplified DNA on custom arrays, which positioned it as an innovator in biotech research before its 2009 closure.[1]
Perlegen rode the early 2000s genomics boom following the Human Genome Project, capitalizing on falling sequencing costs and demand for high-throughput variation mapping.[1][3] Its timing aligned with the rise of personalized medicine and pharmacogenomics, where identifying SNPs via HapMap data accelerated drug discovery and disease association studies.[1][4] Market forces like biotech investments in California (Mountain View base) favored it, influencing the ecosystem by providing foundational data and protocols still referenced in NCBI resources.[1][6] Though defunct, its work advanced tools now integral to modern genomics platforms.
Perlegen Sciences exemplified early genomics ambition but folded in 2009 amid biotech funding challenges, leaving a legacy in variation mapping rather than ongoing operations.[1][2] No revival appears likely given its closure over 15 years ago; instead, its innovations persist through open datasets like HapMap, shaping trends in precision medicine and AI-driven genomics. Its influence endures indirectly via successor technologies, underscoring how pioneering biotech firms fuel long-term ecosystem progress despite short lifespans.[1]
